Published in BMC Cancer on February 05, 2010
Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth. Genes Cancer (2011) 0.87
Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase. Oncotarget (2016) 0.85
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. Br J Pharmacol (2012) 0.83
Onconase downregulates microRNA expression through targeting microRNA precursors. Cell Res (2012) 0.80
A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells. J Immunol Res (2015) 0.76
microRNA-494 and ATF3 the targets of onconase(?). Oncotarget (2016) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res (2006) 44.35
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78
Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Res (2003) 9.30
The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol (1994) 4.15
The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol (2005) 2.45
MicroRNAs in human cancer: from research to therapy. J Cell Sci (2007) 2.00
Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem (2006) 1.99
p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res (1994) 1.95
p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med (2004) 1.74
Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst (2003) 1.59
ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene (2002) 1.55
The regulation of ATF3 gene expression by mitogen-activated protein kinases. Biochem J (2007) 1.52
Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res (2000) 1.43
Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer (2006) 1.39
GeneInfoViz: constructing and visualizing gene relation networks. In Silico Biol (2004) 1.35
Ribonucleases as novel chemotherapeutics : the ranpirnase example. BioDrugs (2008) 1.31
Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem (2002) 1.27
Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res (2003) 1.27
Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest (2005) 1.24
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol (2002) 1.21
Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem (2006) 1.18
The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol (2007) 1.16
Peroxynitrite induces GADD34, 45, and 153 VIA p38 MAPK in human neuroblastoma SH-SY5Y cells. Free Radic Biol Med (2001) 1.13
Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis. J Cell Physiol (2001) 1.09
Interleukin-24 and its receptors. Immunology (2005) 1.02
Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases. Exp Cell Res (1999) 1.02
Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther (2004) 1.02
A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res (2006) 1.02
Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle (2003) 1.01
Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy? Expert Opin Biol Ther (2007) 1.00
Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther (2005) 1.00
Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB. Int J Oncol (2004) 0.97
A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol Pharmacol (2005) 0.94
Characterization of the mechanism of cellular and cell free protein synthesis inhibition by an anti-tumor ribonuclease. Biochem Biophys Res Commun (1994) 0.91
Phase-I human clinical-trial of onconase(r) (p-30 protein) administered intravenously on a weekly schedule in cancer-patients with solid tumors. Int J Oncol (1993) 0.90
Activation of caspases and serine proteases during apoptosis induced by onconase (Ranpirnase). Exp Cell Res (2002) 0.89
Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines. Cancer Biol Ther (2008) 0.87
Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther (2005) 0.85
The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo (2007) 0.84
Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol (2006) 0.82
Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs. Curr Pharm Des (2007) 0.82
A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs (2001) 0.81
Cyclooxygenase activity of cultured human mesothelial cells. Prostaglandins (1993) 0.81
A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells. Mol Cancer Ther (2008) 0.81
Perturbations of the AKT signaling pathway in human cancer. Oncogene (2005) 6.64
Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet (2011) 4.26
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med (2002) 2.56
BAP1 and cancer. Nat Rev Cancer (2013) 2.23
Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol (2008) 2.20
TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A (2006) 2.14
p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem (2001) 2.05
Chromosomal imbalances in human lung cancer. Oncogene (2002) 2.00
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A (2008) 1.97
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis (2004) 1.92
T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell (2010) 1.85
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J (2004) 1.85
GIPC is recruited by APPL to peripheral TrkA endosomes and regulates TrkA trafficking and signaling. Mol Cell Biol (2006) 1.85
The pathogenesis of mesothelioma. Semin Oncol (2002) 1.80
APPL1 associates with TrkA and GIPC1 and is required for nerve growth factor-mediated signal transduction. Mol Cell Biol (2006) 1.78
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res (2007) 1.76
Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem (2004) 1.75
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res (2007) 1.72
RNA2D3D: a program for generating, viewing, and comparing 3-dimensional models of RNA. J Biomol Struct Dyn (2008) 1.72
Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem (2002) 1.70
The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol (2005) 1.60
Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res (2003) 1.58
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther (2004) 1.58
Cellular and molecular parameters of mesothelioma. J Cell Biochem (2006) 1.57
High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer (2003) 1.52
Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene (2005) 1.48
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol (2007) 1.46
Age-dependent mobilization of circulating endothelial progenitor cells in infants and young children undergoing cardiac surgery with cardiopulmonary bypass. Cytokine (2009) 1.45
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene (2002) 1.44
Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene (2005) 1.41
A mouse model recapitulating molecular features of human mesothelioma. Cancer Res (2005) 1.39
mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res (2009) 1.39
Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci U S A (2009) 1.38
Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets (2013) 1.33
Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol (2004) 1.33
Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood (2012) 1.29
Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med (2011) 1.27
Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem (2002) 1.27
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol (2002) 1.21
Human follicle-stimulating hormone (FSH) receptor interacts with the adaptor protein APPL1 in HEK 293 cells: potential involvement of the PI3K pathway in FSH signaling. Biol Reprod (2004) 1.21
Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res (2004) 1.20
A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice. Cancer Res (2008) 1.19
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer (2011) 1.18
Protein kinase C phosphorylation disrupts Na+/H+ exchanger regulatory factor 1 autoinhibition and promotes cystic fibrosis transmembrane conductance regulator macromolecular assembly. J Biol Chem (2007) 1.18
FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis. Cell Cycle (2009) 1.15
Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol (2004) 1.13
A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther (2004) 1.11
Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype. Oncogene (2004) 1.11
SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res (2005) 1.11
The hydrophobic effect: a new insight from cold denaturation and a two-state water structure. Crit Rev Biochem Mol Biol (2002) 1.10
High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer (2009) 1.10
Akt1 and Akt2 differently regulate muscle creatine kinase and myogenin gene transcription in insulin-induced differentiation of C2C12 myoblasts. Endocrinology (2002) 1.09
Association of Lbc Rho guanine nucleotide exchange factor with alpha-catenin-related protein, alpha-catulin/CTNNAL1, supports serum response factor activation. J Biol Chem (2002) 1.08
Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat (2013) 1.08
Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci (2010) 1.08
Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol (2009) 1.07
Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res (2012) 1.06
Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition. AIDS (2003) 1.06
Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res (2004) 1.06
Appl1 is dispensable for mouse development, and loss of Appl1 has growth factor-selective effects on Akt signaling in murine embryonic fibroblasts. J Biol Chem (2009) 1.06
HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol (2007) 1.05
Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer (2010) 1.04
Loss of GATA6 leads to nuclear deformation and aneuploidy in ovarian cancer. Mol Cell Biol (2009) 1.03
The cytotoxic ribonuclease onconase targets RNA interference (siRNA). Cell Cycle (2008) 1.03
Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res (2004) 1.02
SV40 infection induces telomerase activity in human mesothelial cells. Oncogene (2002) 1.01
Cytogenetics and molecular genetics of lung cancer. Am J Med Genet (2002) 1.00
ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer (2011) 1.00
Increased expression of pigment epithelium-derived factor in aged mesenchymal stem cells impairs their therapeutic efficacy for attenuating myocardial infarction injury. Eur Heart J (2011) 1.00
CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proc Natl Acad Sci U S A (2012) 0.99
Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One (2011) 0.99
Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet (2013) 0.97
A novel mechanism of late gene silencing drives SV40 transformation of human mesothelial cells. Cancer Res (2008) 0.97
Retracted Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53. J Biol Chem (2012) 0.97
Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB. Int J Oncol (2004) 0.97
Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma. J Proteome Res (2006) 0.97
GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res (2010) 0.96
Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther (2010) 0.95
Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling. Cancer Res (2010) 0.94
Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer (2009) 0.94
Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Lett (2006) 0.93
p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance. Mol Cell Biol (2004) 0.93
DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC. J Biol Chem (2009) 0.93
The genetics of renal oncocytosis: a possible model for neoplastic progression. Cancer Genet Cytogenet (2004) 0.93
A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. Genes Cancer (2010) 0.93
Retracted ArgBP2gamma interacts with Akt and p21-activated kinase-1 and promotes cell survival. J Biol Chem (2005) 0.93